EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Effect of Anti‐S100A4 Monoclonal Antibody Treatment on Experimental Skin Fibrosis and Systemic Sclerosis–Specific Transcriptional Signatures in Human Skin

Thuong Trinh-Minh, Andrea-Hermina Györfi iD, Michal Tomcik, Cuong Tran-Manh, Xiang Zhou, Nicholas Dickel, Bilgesu Safak Tümerdem, Alexander Kreuter, Sven-Niklas Burmann, Signe Vedel Borchert, Rizwan Iqbal Hussain, Jonas Hallén und 3 weitere

Arthritis & Rheumatology · 2024-05 · 76 (5) · 783-795

DOI: 10.1002/art.42781 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Arthritis & Rheumatology, online erschienen am 15.02.2024. Verfasst von Thuong Trinh-Minh und 14 weiteren Autor:innen. Beteiligte Einrichtung: University Hospital Düsseldorf and Heinrich-Heine University, Düsseldorf, Germany. Hauptthemen laut MEDLINE: Scleroderma, Systemic, S100 Calcium-Binding Protein A4, Skin, Fibrosis. Die Arbeit wurde bisher 25-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: German Research Foundation, Wilhelm-Sander-Foundation, Else-Kröner-Fresenius-Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

S100A4 is a DAMP protein. S100A4 is overexpressed in patients with systemic sclerosis (SSc), and levels correlate with organ involvement and disease activity. S100A4 −/− mice are protected from fibrosis. The aim of this study was to assess the antifibrotic effects of anti‐S100A4 monoclonal antibody (mAb) in murine models of SSc and in precision cut skin slices of patients with SSc.

Methods

The effects of anti‐S100A4 mAbs were evaluated in a bleomycin‐induced skin fibrosis model and in Tsk‐1 mice with a therapeutic dosing regimen. In addition, the effects of anti‐S100A4 mAbs on precision cut SSc skin slices were analyzed by RNA sequencing.

Results

Inhibition of S100A4 was effective in the treatment of pre‐established bleomycin‐induced skin fibrosis and in regression of pre‐established fibrosis with reduced dermal thickening, myofibroblast counts, and collagen accumulation. Transcriptional profiling demonstrated targeting of multiple profibrotic and proinflammatory processes relevant to the pathogenesis of SSc on targeted S100A4 inhibition in a bleomycin‐induced skin fibrosis model. Moreover, targeted S100A4 inhibition also modulated inflammation‐ and fibrosis‐relevant gene sets in precision cut SSc skin slices in an ex vivo trial approach. Selected downstream targets of S100A4, such as AMP‐activated protein kinase, calsequestrin‐1, and phosphorylated STAT3, were validated on the protein level, and STAT3 inhibition was shown to prevent the profibrotic effects of S100A4 on fibroblasts in human skin.

Conclusion

Inhibition of S100A4 confers dual targeting of inflammatory and fibrotic pathways in complementary mouse models of fibrosis and in SSc skin. These effects support the further development of anti‐S100A4 mAbs as disease‐modifying targeted therapies for SSc.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Scleroderma, SystemicS100 Calcium-Binding Protein A4SkinFibrosisAntibodies, MonoclonalBleomycinDisease Models, AnimalAnimalsHumansMiceSTAT3 Transcription FactorFemale

Substanzen

S100 Calcium-Binding Protein A4Antibodies, MonoclonalBleomycinSTAT3 Transcription FactorS100A4 protein, human

Autor:innen und Institutionen

  • University Hospital Düsseldorf and Heinrich-Heine University, Düsseldorf, Germany.
  • Charles University, Prague, Czech Republic.
  • Friedrich-Alexander University of Erlangen-Nürnberg, Erlangen, Germany.
  • Helios St. Elisabeth Klinik Oberhausen, University Witten-Herdecke, Oberhausen, and Helios St. Johannes Klinik Duisburg, Duisburg, Germany.
  • Helios St. Elisabeth Klinik Oberhausen, University Witten-Herdecke, Oberhausen, Germany.
  • Arxx Therapeutics, Oslo, Norway, and Roskilde University, Roskilde, Denmark.

ORCID-Profile: Andrea-Hermina Györfi, Jörg H W Distler

Förderung

  • German Research Foundation
  • Wilhelm-Sander-Foundation
  • Else-Kröner-Fresenius-Foundation
  • German Federal Ministry of Education and Research (BMBF)
  • MASCARA program
  • Award of Medicine of the Ernst Jung Foundation
  • BMBF, CompLS program
  • Ministry of Health Czech Republic

Zitieren

APA

Trinh-Minh, T., Györfi, A. H., Tomcik, M., Tran-Manh, C., Zhou, X., Dickel, N., Tümerdem, B. S., Kreuter, A., Burmann, S. N., Borchert, S. V., Hussain, R. I., Hallén, J., Klingelhöfer, J., Kunz, M., & Distler, J. H. W. (2024). Effect of Anti‐S100A4 Monoclonal Antibody Treatment on Experimental Skin Fibrosis and Systemic Sclerosis–Specific Transcriptional Signatures in Human Skin. Arthritis & Rheumatology, 76(5), 783-795. https://doi.org/10.1002/art.42781

Vancouver

Trinh-Minh T, Györfi AH, Tomcik M, Tran-Manh C, Zhou X, Dickel N, et al. Effect of Anti‐S100A4 Monoclonal Antibody Treatment on Experimental Skin Fibrosis and Systemic Sclerosis–Specific Transcriptional Signatures in Human Skin. Arthritis & Rheumatology. 2024;76(5):783-795. doi:10.1002/art.42781

BibTeX
@article{TrinhMinh2024,
  author = {Trinh-Minh, Thuong and Györfi, Andrea-Hermina and Tomcik, Michal and Tran-Manh, Cuong and Zhou, Xiang and Dickel, Nicholas and Tümerdem, Bilgesu Safak and Kreuter, Alexander and Burmann, Sven-Niklas and Borchert, Signe Vedel and Hussain, Rizwan Iqbal and Hallén, Jonas and Klingelhöfer, Jörg and Kunz, Meik and Distler, Jörg H W},
  title = {Effect of Anti‐S100A4 Monoclonal Antibody Treatment on Experimental Skin Fibrosis and Systemic Sclerosis–Specific Transcriptional Signatures in Human Skin},
  journal = {Arthritis & Rheumatology},
  year = {2024},
  volume = {76},
  number = {5},
  pages = {783--795},
  doi = {10.1002/art.42781}
}
Kostenlos starten →